BioCentury | Jul 11, 2016
Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
BC Week In Review | May 23, 2016
Clinical News

TRV027: Phase IIb data

Top-line data from the double-blind, international Phase IIb BLAST-AHF trial in 618 patients with AHF showed that IV TRV027 plus standard of care (SOC) missed the primary endpoint of improving a composite of mortality, worsening...
BC Extra | May 17, 2016
Clinical News

Trevena's TRV027 misses heart failure endpoint

Trevena Inc. (NASDAQ:TRVN) slipped $0.50 to $6.32 on Monday after its TRV027 missed the primary and secondary endpoints in the Phase IIb BLAST-AHF study to treat acute heart failure (AHF). The company did not disclose...
BC Week In Review | Mar 16, 2015
Clinical News

TRV027: Phase IIb ongoing

A DSMB recommended continuation of the double-blind Phase IIb BLAST-AHF trial comparing 1, 5 and 25 mg/hour IV TRV027 given continuously for 48-96 hours plus standard therapy vs. placebo plus standard therapy after an interim...
BC Extra | Dec 6, 2014
Financial News

Trevena raises $45M in follow-on

Trevena Inc. (NASDAQ:TRVN) raised $45 million through the sale of 11.3 million shares at $4 in a follow-on underwritten by Barclays; Cowen; Jefferies; JMP; and Needham. Trevena proposed to raise $40 million on Nov. 20....
BC Extra | Nov 21, 2014
Financial News

Trevena planning $40M follow-on

Neurology company Trevena Inc. (NASDAQ:TRVN) proposed to raise $40 million in a follow-on underwritten by Barclays; Cowen; Jefferies; JMP; and Needham. Trevena is developing GPCR ligands that activate or block specific signaling pathways mediated through...
BC Extra | Feb 1, 2014
Financial News

Trevena, Cara price IPOs

Neurology company Trevena Inc. (NASDAQ:TRVN) and pain play Cara Therapeutics Inc. (NASDAQ:CARA) both raised money in IPOs on Friday. Trevena raised $64.8 million through the sale of a bumped-up number of shares at its proposed...
BC Extra | Jan 30, 2014
Financial News

Ultragenyx, Flexion, Trevena amend IPOs

Orphan drug company Ultragenyx Pharmaceutical Inc. (Novato, Calif.), pain play Flexion Therapeutics Inc. (Burlington, Mass.) and neurology company Trevena Inc. (King of Prussia, Pa.) all amended planned IPOs on NASDAQ on Wednesday. Ultragenyx bumped up...
BC Week In Review | Jan 20, 2014
Clinical News

TRV027: Phase IIb started

Trevena began the double-blind Phase IIb BLAST-AHF trial to compare 1, 5 and 25 mg/hour IV TRV027 administered for 48-96 hours plus standard therapy vs. placebo plus standard therapy in about 500 patients with AHF....
BC Extra | Nov 21, 2013
Financial News

Trevena postpones IPO

Trevena Inc. (King of Prussia, Pa.) postponed its IPO, citing market conditions. Earlier this month, the company amended its IPO and said it planned to sell 5.8 million shares at $12-$14. At the $13 midpoint,...
Items per page:
1 - 10 of 29